Discover trends, market shifts, and competitive outlooks for the onpattro global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Onpattro Market In 2029?

In recent times, the market size of onpattro has seen a hike of XX (HCAGR). Predictions for its growth point towards a rise from $XX million in 2024, eventually reaching $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The historical growth of this market is related to factors such as the increasing instance of hereditary transthyretin-mediated amyloidosis, a growing awareness of uncommon diseases, enhanced investments in research and development, a larger elderly population, and a surge in healthcare expenditure.

Predictions indicate that the onpattro market size will experience significant growth of XX% (FCAGR) in the coming years, culminating in a value of $XX million by 2029 with a compounded annual growth rate of XX%. Projected growth within the next few years can be linked to factors such as cooperation and licensing, regulatory backing, the escalating number of chronic diseases, growing biopharmaceutical partnerships, and a rising incidence of transthyretin amyloidosis cases. Furthermore, the forecast period is likely to see a surge in the adoption of ribonucleic acid-based treatments, an increase in orphan drug attributions, the integration of digital health instruments, a shift towards more personalized healthcare, and technological strides in drug delivery.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp

What Are the Core Growth Drivers Propelling the Onpattro Market Forward?

The escalating instances of hereditary transthyretin-mediated amyloidosis (hATTR) are anticipated to boost the expansion of the onpattro market. hATTR is an uncommon genetic condition where faulty TTR proteins create destructive clusters, impacting the heart and nerves. The increase in hATTR cases can be attributed to improved diagnostic methods, genetic screenings, and a heightened awareness leading to more identified cases. Onpattro is a treatment for hATTR that works by inhibiting the transthyretin (TTR) gene, which lessens the creation of amyloid proteins to stave off organ injury. Taking, for instance, data from Verywell Health, an American health knowledge platform, in February 2024, they reported that worldwide, 5,500–38,500 individuals are impacted by hATTR. In the U.S., estimates varied from 104 to 3,847 hATTR cases with polyneuropathy, calling attention to a significant rate of underdiagnosis. For these reasons, the accelerating instances of hereditary transthyretin-mediated amyloidosis are pushing the growth of the onpattro market forward.

What Segment Types Define the Onpattro Market Structure?

The onpattro market covered in this report is segmented –

1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses

2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies

3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20169&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Onpattro Market?

North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Emerging Trends that Are Influencing the Onpattro Industry Evolution?

One key trend observed in the onpattro market revolves around the expansion of the drug’s uses through supplemental drug applications, in an effort to increase its market reach and cater to a diverse array of patient requirements. The general purpose of these applications is to widen the scope of a drug’s approved use, for instance, by focusing on new indications, different demographic groups, or novel formulations, thereby expanding its therapeutic effectiveness and market viability. As an example, Alnylam Pharmaceuticals, an American pharmaceutical firm, announced their Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran) being accepted in February 2023. This particular treatment is aimed at addressing cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO is a therapeutic RNA interference (RNAi) that is designed to target specifically the transthyretin (TTR) protein, abnormal accumulations of which can cause serious complications, such as cardiomyopathy, in patients with ATTR amyloidosis. Initially, the drug received approval in 2018 to treat polyneuropathy related to hereditary ATTR amyloidosis. The decision to submit the recent sNDA was based on the outcome of the APOLLO-B Phase III trial, which showed that patisiran significantly enhanced functional capacity and life quality in cardiomyopathy patients when compared with a placebo.

View the full report here:

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

What Is the Definition of the Onpattro Market?

Onpattro (patisiran) is an FDA-approved medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disorder. It works by targeting and silencing the transthyretin (TTR) gene to reduce the production of amyloid proteins that cause organ damage. Onpattro is delivered via intravenous infusion and helps manage symptoms and improve the quality of life for affected patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20169

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model